Anna Eramo - Sep 10, 2025 Form 3 Insider Report for LB PHARMACEUTICALS INC (LBRX)

Role: Chief Medical Officer
Signature: /s/ Marc Panoff, Attorney-in-Fact
Stock symbol: LBRX
Transactions as of: Sep 10, 2025
Transactions value $: $0
Form type: 3
Date filed: 9/10/2025, 07:19 PM
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Eramo Anna	Chief Medical Officer	C/O LB PHARMACEUTICALS INC, ONE PENNSYLVANIA PLAZA, SUITE 1025, NEW YORK	/s/ Marc Panoff, Attorney-in-Fact	2025-09-10	0002030921

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	LBRX	Common Stock						3.59K	Sep 10, 2025	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	LBRX	Employee Stock Option (Right to Buy)							Sep 10, 2025	Common Stock	26.9K	$41.84	Direct	F1
holding	LBRX	Employee Stock Option (Right to Buy)							Sep 10, 2025	Common Stock	6.28K	$41.84	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	One fourth (1/4) of the shares subject to the option award vested on August 25, 2024 and the remaining shares subject to the option vested or shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.
F2	One fourth (1/4) of the shares subject to the option award vested on June 28, 2025 and the remaining shares subject to the option vested or shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.